Novonesis

Novonesis, established in 2024 through the strategic merger of Novozymes and Chr. Hansen, is a prominent global biosolutions company. It specializes in harnessing advanced microbiology, enzyme technology, and fermentation processes to drive improvements in industrial efficiency, environmental sustainability, and product performance. The company's foundation in 2024 marks a significant consolidation of expertise in biological innovation, aiming to address complex global challenges through science-driven solutions that enhance resource utilization and reduce ecological impact.

Serving a diverse array of critical sectors including food, agriculture, healthcare, energy, and industrial manufacturing, Novonesis develops science-based biological solutions. These innovations are designed to foster healthier lives, enable more sustainable production methods, and minimize environmental footprints across worldwide markets. With an employee base exceeding 10,000 individuals, the company is structured to deliver comprehensive biosolution strategies and research initiatives. Meet Novonesis's team to understand the expertise driving these advancements in biotechnology and applied sciences.

The company reports substantial revenue of $4.8B, underscoring its significant market presence and financial scale within the biosolutions sector. Operating within the Manufacturing General and Manufacturing industries, Novonesis leverages its singular primary location to coordinate its extensive global operations and product development pipelines. Its digital presence is maintained via www.novonesis.com, providing a gateway to its extensive portfolio of biosolution offerings, technological capabilities, and commitment to a sustainable future.